Trade Aquestive Therapeutics, Inc. - AQST CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0330 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.7285 |
| Open | 2.8785 |
| 1-Year Change | -34.21% |
| Day's Range | 2.7685 - 2.9285 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 2.7985 | 0.0100 | 0.36% | 2.7885 | 2.9385 | 2.7485 |
| Apr 22, 2025 | 2.7285 | 0.1600 | 6.23% | 2.5685 | 2.7385 | 2.5685 |
| Apr 21, 2025 | 2.5685 | 0.1000 | 4.05% | 2.4685 | 2.6485 | 2.4385 |
| Apr 17, 2025 | 2.4885 | 0.0300 | 1.22% | 2.4585 | 2.5585 | 2.4485 |
| Apr 16, 2025 | 2.4885 | 0.0200 | 0.81% | 2.4685 | 2.5685 | 2.4485 |
| Apr 15, 2025 | 2.5385 | 0.0300 | 1.20% | 2.5085 | 2.5985 | 2.4085 |
| Apr 14, 2025 | 2.5085 | 0.0900 | 3.72% | 2.4185 | 2.5385 | 2.3685 |
| Apr 11, 2025 | 2.4485 | 0.1100 | 4.70% | 2.3385 | 2.4785 | 2.3385 |
| Apr 10, 2025 | 2.4085 | -0.0600 | -2.43% | 2.4685 | 2.4885 | 2.3085 |
| Apr 9, 2025 | 2.5585 | 0.2700 | 11.80% | 2.2885 | 2.6085 | 2.1785 |
| Apr 8, 2025 | 2.3285 | -0.2900 | -11.08% | 2.6185 | 2.6285 | 2.2785 |
| Apr 7, 2025 | 2.5885 | 0.1000 | 4.02% | 2.4885 | 2.7185 | 2.3985 |
| Apr 4, 2025 | 2.6885 | -0.0300 | -1.10% | 2.7185 | 2.7885 | 2.5985 |
| Apr 3, 2025 | 2.8485 | 0.0500 | 1.79% | 2.7985 | 2.9185 | 2.7985 |
| Apr 2, 2025 | 3.0185 | 0.2900 | 10.63% | 2.7285 | 3.0285 | 2.7285 |
| Apr 1, 2025 | 2.8385 | -0.0300 | -1.05% | 2.8685 | 3.0285 | 2.7985 |
| Mar 31, 2025 | 2.8685 | 0.0100 | 0.35% | 2.8585 | 2.9385 | 2.7985 |
| Mar 28, 2025 | 2.9985 | -0.1100 | -3.54% | 3.1085 | 3.1785 | 2.9585 |
| Mar 27, 2025 | 3.1885 | 0.1500 | 4.94% | 3.0385 | 3.2185 | 3.0385 |
| Mar 26, 2025 | 3.1085 | -0.0400 | -1.27% | 3.1485 | 3.1685 | 3.0385 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Aquestive Therapeutics, Inc. Company profile
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).
Equity composition
Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.
| Industry: | Pharmaceuticals (NEC) |
30 Technology Dr
WARREN
NEW JERSEY 07059-5166
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com